Muhammet Özbilen: Is the IV Iron Given to Hospitalized Patients Sufficient?
Muhammet Özbilen, Associate Professor Doctor at Ordu University, shared a post on LinkedIn about a recent article by Joséphine A. Cool et al. published in AJH, adding:
“Is the IV iron given to hospitalized patients sufficient?
A paper published last month in the American Journal of Hematology paints a vivid picture.
The investigation was carried out at Harvard Medical School’s training hospital.
- More than 200,000 hospital admissions from 5 years were studied.
- Only 31.5% of anemic individuals had their iron levels checked.
- Only half (54%) of patients with iron deficiency anemia (IDA) were given iron supplements.
- The calculated median iron deficiency in patients receiving IV iron was 1,847 mg, while the median amount provided was only 500 mg.
So ‘Mind the Gap’ expresses just this: there is a 1,364 mg difference in the IV iron dose provided.
The cause for this big disparity can be described as follows:
- Iron measurements are commonly neglected when anemia is not the main reason for admission.
- The majority of DEA patients in this investigation were normocytic (median MCV: 86), contrary to expectations of microcytosis.
- Ferric gluconate is the most often used IV iron formulation with a low daily maximum dose. However, it is insufficient for non-dialysis patients and requires numerous doses.
- The present hospital treatment approach prioritizes acute stabilization over chronic disease management.
However, appropriate iron therapy has been shown to normalize hemoglobin levels within 8 weeks, reducing the need for outpatient IV iron.
Conclusion: DEA is underdiagnosed and undertreated in the inpatient context. To address this, physician education and system-level interventions are required.”
Title: Mind the Gap: Underdosing of Intravenous Iron in a Hospitalized Patient Population With Iron-Deficiency Anemia
Authors: Joséphine A. Cool, Linnea M. Wilson, Justine Blum, Jason A. Freed, Shoshana J. Herzig

Stay updated on all scientific advances with Hemostasis Today.
-
Nov 9, 2026, 13:48PF4-ELISA–Negative HIT: Are We Missing a New Class of Anti-PF4 Immunothrombotic Disease?
-
Nov 9, 2026, 13:07Nandini Sadasivam: Gene Therapy for Sickle Cell Disease and Thalassaemia
-
Nov 9, 2026, 13:04Raising Awareness of Bleeding Disorders in Women and Girls – EHC
-
Nov 9, 2026, 12:59Rahul Bohra: Exploring the Complex Mechanisms of Sickle Cell Disease
-
Nov 9, 2026, 12:53Three Years of Movement and Thrombosis Awareness in the Czech Republic – World Thrombosis day
-
Nov 9, 2026, 12:51Octavio Marques Pontes-Neto: Intensive Blood-Pressure Control Reduces Cardiovascular Events After Ischemic Stroke
-
Nov 9, 2026, 12:49Irma Bagdoniene: What Really Makes Us Live Longer
-
Nov 9, 2026, 12:47Imo Akpan: Announcing the 2027 Women’s Hematology Summit
-
Nov 9, 2026, 12:45Shadi Yaghi: Rethinking Antithrombotic Therapy After Stroke